Syntimmune Inc., of New York, said research findings for SYNT002 – the company's second most advanced pipeline program and lead monoclonal antibody therapy targeting albumin-FcRn interactions – demonstrate that inhibition of FcRn (neonatal Fc receptor) provides protection against toxin-induced liver injury and causes removal of toxins from circulation via a newly described mechanism that is engaged by SYNT002.